Clinical Trials Logo

Filter by:
NCT ID: NCT02412787 Completed - Hunter Syndrome Clinical Trials

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

Start date: April 14, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

This extension study will allow participants that completed Study HGT-HIT-094 to continue receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving Elaprase treatment and begin concurrent IT treatment for those that did not receive idursulfase IT treatment in Study HGT-HIT-094.

NCT ID: NCT02412657 Completed - Pain Clinical Trials

Intravenous Dexamethasone to Increase the Analgesic Duration of Interscalene Block

Start date: September 2014
Phase: N/A
Study type: Interventional

Interscalene brachial plexus block provides excellent but time limited analgesia. Intravenous dexamethasone increases the analgesic duration of a single-shot interscalene block with ropivacaine for shoulder arthroscopic surgery. We want to evaluate the effect of two different doses (dexamethasone 10 mg i.v. vs 4 mg i.v. vs placebo) on the analgesic duration of a single-shot inter scalene block. Our study hypothesis is that dexamethasone 4 mg i.v. is equivalent to dexamethasone10 mg i.v. in prolonging the analgesic duration of a single-shot interscalene block with ropivacaine.

NCT ID: NCT02412462 Completed - Solid Tumor Clinical Trials

Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy

Start date: April 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy. AB-16B5 is a humanized monoclonal antibody that inhibits the activity of the secreted form of clusterin (sCLU), a potent inducer of the epithelial-to-mesenchymal transition (EMT). Eligible subjects will have a disease that has been refractory to prior therapy and is unlikely to benefit from known therapies.

NCT ID: NCT02412111 Completed - Cystic Fibrosis Clinical Trials

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Start date: June 2015
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.

NCT ID: NCT02411149 Completed - Clinical trials for Total Knee Arthroplasty

Adductor Canal Block and Recovery After Total Knee Replacement Surgery

ACB in TKA
Start date: April 2014
Phase: Phase 4
Study type: Interventional

This study aims to compare the functional recovery of patients undergoing Total Knee Arthroplasty based on the administration of an adductor canal block during their anesthesia treatment

NCT ID: NCT02411110 Completed - Clinical trials for Painful Bladder Syndrome

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

Start date: May 21, 2015
Phase: Phase 2
Study type: Interventional

This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.

NCT ID: NCT02410824 Completed - Astigmatism Clinical Trials

Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism

Start date: April 2015
Phase: N/A
Study type: Interventional

Bilateral dispensing clinical trial of stenfilcon A against etafilcon A for astigmatism.

NCT ID: NCT02410512 Completed - Neoplasms Clinical Trials

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: April 24, 2015
Phase: Phase 1
Study type: Interventional

This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy; or for which standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for which a clinical trial of an investigational agent is a recognized standard of care. Participants will be enrolled in two stages: a dose-escalation stage and an expansion stage.

NCT ID: NCT02409004 Completed - Healthy Clinical Trials

Effects of Rifampin on the Pharmacokinetics of Ataluren

Start date: February 2015
Phase: Phase 1
Study type: Interventional

This will be a single centre, Phase I, open-label, one cohort, one dose level, fixed-sequence, drug interaction study in healthy volunteers. The objective of this study is to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting conditions.

NCT ID: NCT02407860 Completed - Breastfeeding Clinical Trials

Efficacy of an Osteopathic Treatment for Mechanical Sucking Dysfunctions in Newborn

Start date: December 2014
Phase: N/A
Study type: Interventional

Breastfeeding is the physiological and recommended way of feeding newborns as indicated by the World Health Organization, Health Canada and the politics of perinatality 2008-2018 in Quebec. Despite these, mothers who exclusively breastfed their babies are rare. According to Statistics Canada, the first month of life is the most at risk time to wean because of technical difficulties (53% of weaning) including mechanical issues. In Quebec city, despite a supportive network of health care professionals including lactation consultant, many babies are weaned. Lactation consultant are often feeling helpless when facing these mechanical difficulties. The purpose of this study is to determine the efficiency of an osteopathic treatment for newborns presenting breastfeeding mechanical difficulties. The investigators' hypotheses is that an osteopathic treatment integrating in the usual care is more efficient than usual car alone to help healing mechanical breastfeeding issues. The investigators propose a randomized clinical trial on a sample of 90 babies (45 in each group), under six weeks, presenting sucking dysfunctions, in Quebec city (Canada). The control group will receive usual care with a lactation consultant and the intervention group will receive usual care plus an osteopathic treatment. It is a simple blind clinical trial: the osteopath finds out, prior to evaluating the patient, what intervention should be delivered to the baby (assessment alone or standardized osteopathic treatment for infant). The results will ultimately lead to improvements in the existing knowledge on the fields of osteopathy and lactation support, allowing implementation of osteopathic care in the perinatal network.